Willem Westra

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

Our cofounders chatted with San Diego Business Journal about our recent #AACR24 data showing our lead drug candidate works across many cancer types to kill tumor cells but leave healthy cells alone – as well as how our upcoming clinical trial could quickly yield proof-of-concept data. Read the article here (subscription may be required): https://lnkd.in/gR-rCQzE #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

25

We invite all San Diego Biotech Professionals to connect, share ideas, and discuss lab automation, data management and innovation strategies. Hear from Sandor Szalma, former Global Head of Genetics and Systems Biology at Takeda, about his informatics journey. Register Now: https://lnkd.in/guaef_pf #zifo #labdigitalization #digitaltransformation #pharmaceutical #labinformatics #laboperations #dataintegrity #FAIRdata #labautomation #scientificinformatics #drugdevelopment #datamanagement

31

#LanternPharma announced a strategic AI-driven collaboration with #OregonTherapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. https://shorturl.at/alnoZ #TechNews #StayInformed #StayAhead #dailydose #followus #staytuned #stayconnected #technews #technology #trending #trendingnow #trendingnews #explore #explorepage #techdogs

5

Don’t miss the latest episode of The Bio Report podcast, where our CBO Hilary Eaton, PhD joined Daniel Levine for a wide-ranging conversation about the role of #GenerativeAI in drug development, our OpenCRISPR-1 molecule and why we made it open-source. 👉 https://lnkd.in/gkD4iAEt #AI #CRISPR #OpenCRISPR #ProteinDesign #Podcast

20

📣 TODAY at #BPIEast: Join Oren Beske, PhD, ATUM's Amalgamator of Business & Biology, at 12:15pm to learn how you can leverage multiple orthogonal transposases in the genetic engineering of CHO cells. Then stop by Booth #831 to learn how ATUM's services and platforms can increase your productivity, effortlessly! #BPIconf #CellLineDevelopment #Biologics

12

Formation Bio's Melanie Hullings and Laura Fazio, MS will be presenting at PHUSE on July 25th in Pennsylvania. We hope to see you there! -- In the era of AI and advanced analytics propelling data management forward at an exponential rate, partnership between Clinical Data Managers and Clinical Data Scientists is critical. Laura and Mel will discuss how these teams at Formation Bio work together to create fit-for-purpose tools to automate data cleaning, reporting and analytics. They will also share perspectives on where AI-driven solutions will fit into the clinical data ecosystem and solicit feedback on the gaps that still need filling to support real-time data-driven decisions. More confernece details here: https://rb.gy/r2yctv #datascience #biotech #pharma #drugdevelopment #clinicaltrials #clinicaldatamanagement

53

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

1

Profluent is making waves in biopharma with its innovative OpenCRISPR initiative. Leveraging large language models, the startup aims to advance CRISPR gene editing by designing unique proteins entirely through AI. Their approach, grounded in massive protein sequence databases, could vastly expand the possibilities for gene therapy development. In a bold move, Profluent has also made its research available through an open-source license, promoting collaboration and acceleration in the field. Discover how AI is driving the next generation of biopharmaceuticals. #biotech #artificialintelligence

1

Vaidehi Joshi, Director, Discovery Biology at Viscient Bio Inc, graced our 20th BioPharma Drug Discovery event in San Diego, CA with her enlightening presentation on "Three-Dimensional primary cell based liver model predicts clinical outcomes of MASH in vitro" Gain invaluable insights into the future of liver disease research and clinical outcomes prediction!" #BioPharmaNexus #Discovery #invitro #Biology #Procurementdirect #NexusConference #SanDiego #Cell #ClinicalOutcomes #Scientific #USAconference #Disease #NexusConference

127

2 Comments

Don’t miss this opportunity at the Gene Therapy Initiative 1st Annual Symposium on September 19, 2024 to engage our thriving San Diego community of researchers, life sciences, biotechnology and pharmaceutical companies in the gene therapy space. The Gene Therapy Initiative (GTI) Symposium will convene researchers and industry experts to share the latest scientific findings and facilitate new partnerships with the goal of expediting the delivery of stem cell and gene therapy treatments, especially for patients with rare genetic diseases. Program Highlights: *Exploratory talks on innovative gene modifying therapeutics and optimization of existing tools. *Updates on gene therapies that are the subject of academic research and commercial development. *Induced Pluripotent Stem-cell-based disease models to test gene therapies. *Interactive panel on resources and collaboration for developing therapies for rare diseases. *Opportunity to learn about 2024 GTI seed grant funded projects. *Poster session featuring faculty and student research. *Networking hour to foster connectivity amongst attendees. Please note, there is NO CME for this symposium.   For more information and to register, go to: https://lnkd.in/gJuEP_Kv #GeneTherapy #genetherapies #RNAtechnologies #ExVivoGeneTherapy #AAVgenetherapy #research #science #lifesciences #biotechnology #scientificmeeting

12

<!-- Content start --> South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting. “These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab program. About SKYSCRAPER-06 study SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non-small cell lung cancer. Primary endpoints are overall survival (OS) and progression-free survival (PFS). About tiragolumab Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but

1

Dive into the six-base genome in this great Q&A with biomodal’s director of market strategy and corporate development, Tom Charlesworth, and Karen Steward of Technology Networks: Picking Apart the Epigenome To Advance Cancer Research. With the advent of duet evoC, researchers can distinguish both modifications (5mC and 5hmC) in a single experiment from a low input sample. #epigenetics #epigenomics #cancerresearch Read the interview here 👇

13

The biotherapies field is evolving, and AABB’s latest publication, Getting Started in Processing for Biotherapies, offers crucial insights for professionals entering this space. In the September edition of #CellSource, Christina Celluzzi, PhD, MS, CABP(H), spoke with Joseph (Yossi) Schwartz, MD, MPH, CABP, on the book’s significance and how it addresses key topics such as business plans, budget considerations and the role of blood collection facilities in biotherapies. Read the interview 👉 https://bit.ly/3XTXAHo #Biotherapies #CellTherapy #AdvancedTherapies

21